|1.||Zhao, Jun: 16 articles (06/2015 - 11/2009)|
|2.||Shahid, Mohammed: 14 articles (03/2012 - 02/2008)|
|3.||Panagides, John: 12 articles (05/2012 - 01/2007)|
|4.||Mackle, Mary: 11 articles (01/2016 - 01/2011)|
|5.||Szegedi, Armin: 11 articles (12/2015 - 01/2011)|
|6.||McIntyre, Roger S: 8 articles (01/2016 - 11/2009)|
|7.||Alphs, Larry: 8 articles (11/2013 - 01/2007)|
|8.||Cazorla, Pilar: 7 articles (03/2014 - 01/2012)|
|9.||Wong, Erik H F: 6 articles (12/2010 - 02/2008)|
|10.||Citrome, Leslie: 5 articles (06/2014 - 01/2011)|
|1.||Schizophrenia (Dementia Praecox)
05/01/2012 - "The efficacy of asenapine was reported in 3 clinical studies in patients with schizophrenia, 1 each in acute and long-term settings, measured as significant changes in Positive and Negative Syndrome Scale scores over 6 and 52 weeks. "
09/01/2009 - "In two randomized, controlled trials in adult patients with acute schizophrenia, treatment with asenapine reduced from baseline the clinician-assessed Positive and Negative Syndrome Scale (PANSS) total score to a significantly greater extent than placebo at 6 weeks. "
12/01/2012 - "These meta-analyses indicate that the efficacy of asenapine for acute schizophrenia is superior to placebo and comparable to several other SGAs."
04/01/2013 - "As in clinical trials, real-life case reports demonstrate that asenapine is effective in treating the positive symptoms of schizophrenia, both in the acute setting and for relapse prevention. "
01/01/2011 - "Asenapine is a new, second-generation (atypical) antipsychotic medication with demonstrated efficacy for the acute and maintenance treatment of schizophrenia. "
|2.||Bipolar Disorder (Mania)
05/01/2012 - "In addition, efficacy of asenapine was reported in 2 studies in acute mania as well as extension phases of both 9 and 40 weeks, as determined by significant changes in Young Mania Rating Scale scores. "
03/01/2011 - "In two large (both n = 480), well designed, 3-week trials in adult patients with bipolar I disorder, asenapine monotherapy was significantly more effective than placebo at improving mania symptoms, as assessed using the Young Mania Rating Scale total score (YMRS; primary endpoint), with significant differences between the asenapine and placebo groups occurring after 2 days of treatment. "
09/01/2009 - "In two randomized, controlled trials of asenapine monotherapy and in one randomized, controlled trial of adjunctive asenapine therapy in adult patients with bipolar I disorder, sublingual asenapine produced significantly greater reductions from baseline than placebo in clinician-assessed Young Mania Rating Scale (YMRS) total score at 3 weeks. "
02/01/2012 - "The YMRS remission rates and changes from baseline on Clinical Global Impression for Bipolar Disorder for mania and overall illness were significantly better with asenapine at weeks 3 and 12. "
02/01/2012 - "Adjunctive asenapine significantly improved mania versus placebo at week 3 (primary end point) and weeks 2 to 12. "
|3.||Psychotic Disorders (Schizoaffective Disorder)
11/01/2014 - "Our results suggest that: 1) decision regarding treatment discontinuation should be cautious in patients who fail to have an early response to asenapine; 2) different diagnosis (BDor schizoaffective disorder) does not seem to have a significant impact on asenapine efficacy; 3) remission with asenapine is more likely to happen for less severe manic episodes. "
12/01/2015 - "The authors present a case of suspected pseudo-Stauffer's syndrome in a male with treatment refractory schizoaffective disorder following asenapine use. "
11/01/2014 - "We recruited patients with diagnosis of manic episode in bipolar I (BD I) or schizoaffective disorder, with clinical indication to asenapine treatment. "
01/01/2012 - "The pharmacodynamic profile of asenapine provides a rationale for hypothesizing efficacy in the treatment of cognitive deficits in mood and psychotic disorders. "
10/01/2015 - " aims of the current real-world observational study were to evaluate: (i) short-term efficacy of asenapine after 7 days (T0-T1) in patients hospitalized for a manic episode in the course of bipolar I disorder or schizoaffective disorder (group A), (ii) differences in length of stay (LoS), and (iii) rehospitalization compared to a control population (group B) with a 6-month follow-up.Twenty"
|4.||Substance-Related Disorders (Drug Abuse)
12/01/2011 - "A 9- extension trial indicated that 19% of asenapine patients will experience clinically significant weight gain. "
12/01/2015 - "The asenapine groups had a higher incidence of ≥7% weight gain (range, 8.0%-12.0%) versus placebo (1.1%; p < .05). "
02/01/2012 - "Weight gain was consistently lower with asenapine. "
03/01/2011 - "The incidence of clinically significant weight gain (≥ 7% increase from double-blind baseline) was 3.7% with asenapine and 0.5% with placebo. "
12/01/2011 - "The placebo-subtracted rate of clinically significant weight gain (≥7%) with asenapine was approximately 5% during the 3-week acute mania trials. "
|2.||Risperidone (Risperdal Consta)
|3.||Antipsychotic Agents (Antipsychotics)
|5.||N- (2- (4- (1,2- benzisothiazol- 3- yl)- 1- piperazinylmethyl)- 1- cyclohexylmethyl)- 2,3- bicyclo(2.2.1)heptanedicarboximide
|1.||Length of Stay
|4.||Drug Therapy (Chemotherapy)